CD38 and Miyoshi myopathy: In addition, the strong synergistic effects of anti-CD38-IFNα(att) with both bortezomib and lenalidomide indicates that drug combinations may offer an optimal regimen in the clinic, even for bortezomib-refractory MM tumors.